Edwards Lifesciences Corporation (NYSE: EW)
Edwards Lifesciences Corporation (EW), a global company that provides technologies to help treat structural heart disease and helps monitor patients in critical care yesterday received positive results for its Sapien heart valve in a clinical trial. The sapien heart valve will allow heart surgery to take place without opening up the chest cavity which will make the procedure much safer for the patient.
Medical Expert’s Comments
“The PARTNER II Trial is unique in size, distinctive in rigor of execution and exceptional in patient outcomes,” said Craig Smith, M.D., chair, Department of Surgery, and surgeon-in-chief, NewYork-Presbyterian Hospital/Columbia University Medical Center. Smith is the co-principal investigator of the PARTNER II Trial. “In intermediate-risk patients, transcatheter and surgical valve replacements were similar with respect to the combination of mortality and disabling stroke. In this study, TAVR significantly shortened ICU and hospital stays, and, in patients who are candidates for transfemoral access, the SAPIEN XT valve may have additional clinical advantages.” PR Newswire
EW Technical Analysis
EW gapped up in price yesterday to $102.21, up from the prior day’s close of $89.92, which is a 14% increase in price. Taking a look at the daily chart we can see that we are in unchartered territory as EW is currently trading at all time highs. Taking a closer look at the daily chart we can see that EW has been on an overall uptrend dating back to February 9th when it traded at $76.34. EW has a float of 212.90 million shares and is trading over 4.5 times the normal daily trading volume. For trading purposes, my entry point would have been $102.25 looking for a run to $105. My stop loss would have been $101.90, fearing anything below that and the stock would start to fill in the gap up.
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and repair products, which are used to replace or repair a patients diseased or defective heart valve. In addition, it produces pericardial valves from biologically inert animal tissue; and provides heart valve repair therapies, including annuloplasty rings and systems. Further, the company offers critical care products, such as hemodynamic monitoring systems to measure a patients heart function in surgical and intensive care settings; pulmonary artery catheters; and continuous venous oximetry catheter for measuring central venous oxygen saturation. Additionally, its critical care products include disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection; and peripheral vascular products used to treat endolumenal occlusive disease, such as embolectomy catheters for removing blood clots from peripheral blood vessels. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California. Yahoo Finance